These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 24113146

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA.
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [Abstract] [Full Text] [Related]

  • 4. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
    Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M.
    CNS Drugs; 2012 Aug 01; 26(8):691-705. PubMed ID: 22762726
    [Abstract] [Full Text] [Related]

  • 5. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.
    Health Technol Assess; 2009 Oct 01; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
    Mac Avin M, Teeling M, Bennett KE.
    BMJ Open; 2020 Apr 22; 10(4):e035716. PubMed ID: 32327478
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lisdexamfetamine.
    Blick SK, Keating GM.
    Paediatr Drugs; 2007 Apr 22; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB, Raja P, Shukla A.
    Expert Opin Pharmacother; 2013 Jan 22; 14(1):137-45. PubMed ID: 23241144
    [Abstract] [Full Text] [Related]

  • 16. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
    Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.
    J Med Econ; 2013 Nov 22; 16(11):1275-89. PubMed ID: 24004347
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J.
    Clin Ther; 2009 Jan 22; 31(1):142-76. PubMed ID: 19243715
    [Abstract] [Full Text] [Related]

  • 18. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
    Weber J, Siddiqui MA.
    CNS Drugs; 2009 Jan 22; 23(5):419-25. PubMed ID: 19453202
    [Abstract] [Full Text] [Related]

  • 19. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä.
    Duodecim; 2012 Jan 22; 128(5):539-40. PubMed ID: 22486070
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.